Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ATM L804fs ATM S978fs RET M918T |
| Therapy | Everolimus + Vandetanib |
| Indication/Tumor Type | medullary thyroid carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM L804fs ATM S978fs RET M918T | medullary thyroid carcinoma | predicted - sensitive | Everolimus + Vandetanib | Case Reports/Case Series | Actionable | In a clinical case study, addition of Afinitor (everolimus) to Caprelsa (vandetanib) treatment resulted in significant tumor reduction in a medullary thyroid carcinoma patient harboring ATM L804fs*4, ATM S978fs*12, and RET M918T, that achieved prolonged stable disease on Caprelsa (vandetanib) treatment alone (PMID: 27683183). | 27683183 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27683183) | RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. | Full reference... |